Shares of Dr Reddy’s Laboratories surged over 4 percent in early trade on Thursday after the pharmaceutical company delivered a better-than-expected set of Q3 FY26 results, prompting brokerages to turn more constructive on the stock. The stock outlook turned positive despite a year-on-year decline in profit and continued pressure in the US business.